StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 Trial
September 11, 2017 6:16 AM
Bristol-Myers Squibb Company (NYSE: BMY) announced today results from the Phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) in Phase 3 CheckMate -238 Study
September 11, 2017 6:21 AM
Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMat
September 10, 2017 11:55 AM
Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
September 8, 2017 5:49 AM
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Goldman Sachs, Positively Revises EPS Estimates
September 7, 2017 9:53 AM
Wall St. ends flat as media stocks slump, healthcare gains
September 7, 2017 7:39 AM
Bristol-Myers Squibb (BMY) Reports CheckMate-214 Study Evaluating Opdivo in Combination with Yervoy Meets Co-Primary Endpoint, Demonstrating Superior Overall Survival Compared to Sunitinib
September 7, 2017 7:02 AM
